Related Experiment Video

Updated: Jun 27, 2026

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Published on: July 17, 2020

Cdc25A protein phosphatase: a therapeutic target for liver cancer therapies

Z Wang1, S Kar, B I Carr

  • 1Kimmel Cancer Center, Thomas Jefferson University, 233 S 10 Street, Room 519A, Philadelphia, PA, USA.

Anti-Cancer Agents in Medicinal Chemistry
|December 17, 2008
PubMed

Insights

Compound 5, a vitamin K analog, inhibits Cdc25A phosphatase, activating the EGFR-MAPK pathway. This research reveals Cdc25A

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Biochemistry

Background:

  • Cdc25A is a crucial dual-specificity protein phosphatase regulating cell cycle progression.
  • Emerging evidence indicates Cdc25A's involvement in mitogen-activated protein kinase (MAPK) signaling.

Purpose of the Study:

  • To investigate the role of Cdc25A in regulating both cell cycle and MAPK pathways.
  • To explore the effects of vitamin K analogs, specifically Compound 5 (Cpd 5), on Cdc25A activity and downstream signaling.

Main Methods:

  • Inhibition of Cdc25A activity using Compound 5 (Cpd 5).
  • Analysis of the epidermal growth factor receptor (EGFR)-MAPK pathway activation.
  • Assessment of transcription factors CREB and c-Myc expression levels.
  • Quantification of Cdc25A and cyclin D1 expression.

Main Results:

  • Inhibition of Cdc25A by Cpd 5 led to strong, prolonged activation of the EGFR-MAPK pathway.
  • Activated EGFR-MAPK signaling suppressed CREB and c-Myc transcription factors.
  • Decreased expression of Cdc25A and cyclin D1 was observed following Cpd 5 treatment.
  • Other vitamin K analogs, PM20 and fluoro-Cpd 5, also impacted this pathway.

Conclusions:

  • Cdc25A acts as a central regulator linking cell cycle progression and MAPK signaling.
  • Targeting Cdc25A with small molecules like vitamin K analogs offers a potential therapeutic strategy for cancers.
  • Further research into Cdc25A inhibitors may yield new treatments for liver and other cancers.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...